Generic Zantac ( Ranitidine )

Buy cheap Generic Zantac (Ranitidine) without dr prescription at Canadian Pharmacy

Zantac (Ranitidine 150 mg, 300 mg): Comprehensive Patient Information for Canada

Basic Product Information

Mechanism of Action

In simple terms: Zantac is an H2 blocker that reduces the amount of acid your stomach produces. It works by blocking the action of histamine, a natural substance in your body that stimulates acid production. By reducing acid, it helps heal stomach and intestinal ulcers, treat acid reflux, and relieve heartburn. It starts working within one hour and the effect lasts for 10 to 12 hours.

For specialists: Ranitidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those on the gastric parietal cells. Ranitidine inhibits both basal and stimulated gastric acid secretion. It also reduces pepsin output and volume of gastric secretion while not affecting serum gastrin concentration. Ranitidine is a potent H2-receptor antagonist with a longer duration of action and fewer drug interactions compared with cimetidine, as it does not significantly inhibit the hepatic cytochrome P450 enzyme system at usual therapeutic doses. Ranitidine has an elimination half-life of approximately 2 to 3 hours.

Pharmacokinetics

• Absorption: Ranitidine is rapidly absorbed after oral administration, with peak plasma concentrations reached approximately 1 to 3 hours after dosing. The absolute bioavailability is approximately 50%. Food does not significantly affect the extent of absorption.
• Metabolism: Ranitidine undergoes limited hepatic metabolism, with approximately 30% of an oral dose metabolized to N-oxide, S-oxide, and desmethyl derivatives. The remainder is excreted unchanged in the urine. Because ranitidine does not significantly inhibit cytochrome P450 enzymes at usual doses, it has fewer drug interactions than cimetidine.
• Elimination: The elimination half-life is approximately 2 to 3 hours. Ranitidine is eliminated primarily by renal excretion, with approximately 60 to 70% of an intravenous dose excreted unchanged in the urine. The half-life may be prolonged in patients with renal impairment.
• Onset of Action: Following oral administration, the antisecretory effect begins within one hour.
• Duration of Action: The duration of inhibition of gastric secretion by doses of 150 mg and 300 mg is approximately 10 to 12 hours.

Uses in Daily Life and Best Practice Advice

Ranitidine was formerly used in Canada for the treatment of acid-related conditions. All ranitidine products have been withdrawn from the Canadian market since September 2019. The information below reflects the historical use of ranitidine for educational and reference purposes. Patients should consult their physician for alternative therapies.

• Typical Uses: Treatment of duodenal and gastric ulcers; prophylaxis against recurrence of duodenal and gastric ulcers; treatment of reflux esophagitis; prophylaxis of reflux esophagitis; treatment of Zollinger-Ellison syndrome; prophylaxis of stress-induced duodenal and peptic ulcers in seriously ill patients; and treatment of chronic dyspepsia (indigestion).
• Administration: Tablets were taken orally with or without food. The usual dosing was once or twice daily, with the evening dose being particularly important for suppressing nocturnal acid secretion.
• Monitoring: If symptoms did not improve or worsened, patients were advised to consult their physician. For gastric ulcer, the possibility of malignancy had to be excluded before therapy was initiated, as H2-antagonists may mask symptoms associated with carcinoma of the stomach and delay diagnosis.
• Withdrawal: Health Canada stopped the distribution of ranitidine in September 2019 due to potentially high concentrations of the possible carcinogen N-nitrosodimethylamine (NDMA). All ranitidine products were subsequently cancelled post-market or cancelled pre-market.

Morning vs. Evening Dosing

Ranitidine was typically taken once or twice daily. When taken once daily, the dose was usually taken at bedtime to suppress nocturnal acid secretion. When taken twice daily, the doses were taken in the morning and at bedtime. There is no specific clinical recommendation for morning versus evening dosing beyond the bedtime dosing for nocturnal acid suppression.

• Bedtime Dosing: When taken once daily, the standard recommendation was to take ranitidine at bedtime to suppress nocturnal acid secretion.
• Twice-Daily Dosing: When taken twice daily, the doses were taken in the morning and at bedtime.
• Consistency: Patients were advised to take ranitidine at the same times each day to ensure maximum effectiveness.
• Missed Dose: If a dose was missed, it was to be taken as soon as remembered. If it was almost time for the next dose, the missed dose was skipped, and the regular schedule resumed. Two doses were not to be taken at the same time.

Administration With or Without Food

Ranitidine could be taken with or without food. Food does not significantly affect the absorption or effectiveness of ranitidine. For over-the-counter use, the tablet was taken with a glass of water as needed for symptoms, or 10 to 15 minutes before eating food or drinking beverages expected to cause heartburn.

• Take the tablet with a full glass of water.
• Ranitidine could be taken with or without food.
• For over-the-counter use, take 1 tablet at the onset of symptoms, or 10 to 15 minutes before eating food or drinking beverages that cause heartburn.
• Do not take more than 2 tablets in 24 hours unless directed by a doctor.
• Do not take nonprescription ranitidine for more than 14 days in a row without talking with a doctor.

Interaction Warnings

Indications for Ranitidine

"Off-label" means use outside the official approved indication, usually based on current medical guidelines and scientific evidence.

Dosing According to Clinical Indication

Doses should always be adjusted according to the advice of a physician and depending on the patient's health condition. In elderly patients and those with renal or hepatic impairment, the dose was reduced to 150 mg at bedtime for a period of 4 to 8 weeks.

Side Effects and Safety Profile

Guidelines for Correct Use

• Take ranitidine exactly as prescribed by your physician. Do not change your dose without medical advice.
• Take the tablet with a full glass of water, with or without food.
• If taking once daily, take it at bedtime. If taking twice daily, take the doses in the morning and at bedtime.
• Do not take more than the recommended dose.
• Do not take nonprescription ranitidine for more than 14 days in a row without talking with your doctor.
• Do not stop taking prescription ranitidine without consulting your physician.
• If you are pregnant, planning to become pregnant, or breastfeeding, consult your physician before use.
• If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double the dose.
• Keep all medical appointments for monitoring of your condition.
• Store at room temperature in a dry place. Keep out of reach of children.

Alternative Treatment Options

• Famotidine (Pepcid): An H2 blocker that is the go-to replacement for ranitidine. It blocks the same stomach receptors but has not faced the NDMA contamination issue. A typical dose for occasional heartburn is 10 mg to 20 mg, taken once or twice a day. Famotidine 20 mg is equivalent in potency to ranitidine 150 mg and has a longer half-life.
• Cimetidine (Tagamet): An older H2 blocker that is cheaper but can interact with more medications because it inhibits cytochrome P450 enzymes. Adults usually take 200 mg twice daily for short-term relief. Check with a pharmacist first if you are on blood thinners or heart drugs.
• Nizatidine (Axid): An H2 blocker similar to ranitidine. The standard dose is 150 mg once daily for ulcer prevention or 300 mg split into two doses for heartburn. Less commonly used in Canada.
• Proton Pump Inhibitors (PPIs) (e.g., omeprazole, pantoprazole, esomeprazole, lansoprazole): PPIs block acid production at its source, giving stronger and longer-lasting control than H2 blockers. They are preferred for severe GERD, frequent night-time symptoms, or ulcers that do not heal. Typical over-the-counter dosing is 20 mg of omeprazole once daily, taken 30 minutes before breakfast.

Comparison: Ranitidine was a widely used H2 blocker that was distinguished from cimetidine by its fewer drug interactions and longer duration of action. However, all ranitidine products were withdrawn from the Canadian market in 2019 due to NDMA contamination. Famotidine is now the preferred H2 blocker, offering equivalent efficacy with a better safety profile. PPIs are generally more effective for healing severe esophagitis and are the preferred choice for H. pylori eradication regimens. Your physician will determine the best option for your specific condition.

Legal Status, Registration, and Coverage in Canada

• Registration: Ranitidine was formerly authorized for sale in Canada by Health Canada as both a prescription and nonprescription drug. In September 2019, Health Canada stopped the distribution of ranitidine due to potentially high concentrations of the possible carcinogen N-nitrosodimethylamine (NDMA). All ranitidine products were subsequently cancelled post-market or cancelled pre-market. The brand-name Zantac and numerous generic formulations are no longer available in Canada.
• Prescription Status: Not currently available in Canada in any form.
• Coverage: Not applicable. Ranitidine is no longer available through Canadian pharmacies. Patients who were previously taking ranitidine should consult their physician for alternative therapies.
• Pharmacovigilance: Adverse reactions to ranitidine should be reported to Health Canada's MedEffect Canada program.

Recent Research and Clinical Guidelines (2022–2026)

• In November 2025, the FDA approved a reformulated version of ranitidine after a 5-year suspension from the US market. The manufacturer conducted extensive safety testing and manufacturing improvements to address previous concerns, though the news release did not explicitly confirm whether NDMA had been completely removed from the new formulation. This reformulated product has not been approved in Canada.
• Ranitidine was withdrawn years ago in the EU, US, Canada, and Australia due to NDMA contamination. NDMA is classified as a probable human carcinogen and is an intrinsic degradation product of ranitidine.
• A 2025 review of ranitidine alternatives concluded that famotidine is the preferred replacement for ranitidine, as it blocks the same stomach receptors but has not faced the NDMA contamination issue. Famotidine 20 mg is equivalent in potency to ranitidine 150 mg and has a longer half-life.
• Most H2 receptor antagonists, except nizatidine, are considered safe for use during breastfeeding. However, due to the NDMA concerns, ranitidine is no longer recommended for use during pregnancy or breastfeeding.
• The 2026 Canadian clinical practice guidelines continue to recommend famotidine and proton pump inhibitors as the primary alternatives for patients who were previously taking ranitidine.

Availability and Supply in Canada

Ranitidine is no longer available in Canada in any form. Patients who were previously taking ranitidine should consult their physician for alternative therapies such as famotidine or a proton pump inhibitor. Prices and availability information is not applicable as the product has been withdrawn from the Canadian market.

Frequently Asked Questions (FAQ)

1. Is Zantac (ranitidine) available in Canada?
   No. All ranitidine products, including Zantac, were withdrawn from the Canadian market in September 2019 due to concerns about NDMA contamination. The products have been cancelled post-market or cancelled pre-market and are no longer available through Canadian pharmacies.
2. Why was ranitidine withdrawn from the Canadian market?
   Health Canada stopped the distribution of ranitidine in September 2019 after tests showed that some ranitidine products contained N-nitrosodimethylamine (NDMA), a probable human carcinogen, at levels above what is considered safe. NDMA levels were found to increase over time under normal storage conditions.
3. What should I take instead of ranitidine?
   Famotidine (Pepcid) is the preferred replacement for ranitidine. It is an H2 blocker that works the same way and has not faced the NDMA contamination issue. Proton pump inhibitors (PPIs) such as omeprazole, pantoprazole, and esomeprazole are also effective alternatives, particularly for more severe symptoms. Consult your physician or pharmacist for the best option for your condition.
4. What was the difference between ranitidine 150 mg and 300 mg?
   The 300 mg dose was typically used for the treatment of active duodenal and gastric ulcers, taken once daily at bedtime. The 150 mg dose was used for maintenance therapy to prevent ulcer recurrence, for treatment of reflux esophagitis, and as a twice-daily regimen for active ulcers. The 150 mg dose was also used in patients with renal impairment.
5. Can I still get ranitidine from another country?
   Ranitidine has been withdrawn from the market in Canada, the US, the EU, and Australia. While a reformulated version was approved in the US in 2025, it has not been approved in Canada. Importing ranitidine from another country is not recommended without consulting Health Canada and your physician.
6. Is famotidine as effective as ranitidine?
   Yes. Famotidine 20 mg is equivalent in potency to ranitidine 150 mg. Famotidine has a longer half-life and does not have the drug interactions with medications metabolized by the P450 enzymes that ranitidine had. It is considered the go-to replacement for ranitidine.
7. What are the serious side effects of ranitidine?
   Serious side effects include leukopenia, thrombocytopenia, acute porphyric attacks, severe allergic reactions, hepatitis, and pneumonia. However, the primary reason for withdrawal was the presence of NDMA, a probable carcinogen, rather than these clinical side effects.
8. Can I take famotidine if I was previously taking ranitidine?
   Yes. Famotidine is the recommended alternative for most patients who were taking ranitidine. However, you should consult your physician before switching, especially if you have kidney or liver problems, are pregnant or breastfeeding, or are taking other medications.
9. Was ranitidine safe during pregnancy?
   Ranitidine was generally considered safe for short-term use during pregnancy, but it crosses the placenta and safety has not been fully established. Due to the NDMA contamination concerns, ranitidine is no longer recommended for use during pregnancy or breastfeeding. Famotidine is considered safe during pregnancy and breastfeeding.
10. What is NDMA and why is it dangerous?
    NDMA (N-nitrosodimethylamine) is a probable human carcinogen. It is a degradation product that can form in ranitidine during storage, and levels increase over time and at higher temperatures. Long-term exposure to NDMA may increase the risk of cancer.

How to buy Generic Zantac without rx in Canada.